Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Centre Hospitalier Esquirol
Information provided by (Responsible Party):
Jean-Christophe Dumont, Centre Hospitalier Esquirol Identifier:
First received: September 11, 2013
Last updated: August 5, 2015
Last verified: July 2015

September 11, 2013
August 5, 2015
September 2013
August 2016   (Final data collection date for primary outcome measure)
number of fibromyalgia subjects maintaining a clinical improvement with rTMS maintenance sessions during 6 months [ Time Frame: 210 days ]

= number of fibromyalgia subjects maintaining a clinical improvement after a prior rTMS treatment (15 sessions in 3 weeks)and maintenance rTMS sessions administered at 42, 63, 84, 105, 126, 147, 168, 189, 210 days after inclusion in comparison with sham maintenance sessions.

clinical improvement is described as a 30% decrease from baseline in pain feeling (visual analogue scale) and a response ≥ 6 for the Patient's global impression of Change.

effect will be considered as maintained if criteria of clinical improvement present after 3 week rTMS treatment are conserved at 6 months rTMS or sham maintenance sessions.

Same as current
Complete list of historical versions of study NCT01942538 on Archive Site
number of rTMS responders at 3week-rTMS treatment [ Time Frame: 21 days ]
Same as current
Not Provided
Not Provided
Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia
Study of the Effectiveness of Maintenance rTMS Sessions for 6 Months Versus Placebo in Subjects With Fibromyalgia Responders to 3 Week-rTMS Treatment
Maintenance rTMS sessions after a successful 3week-rTMS treatment for subjects with fibromyalgia may maintain the clinical improvement.
In a previous pilot study, a 3 week treatment with rTMS in fibromyalgia subjects induced a 40% improvement of pain feeling. Three months later, the pain level was still significantly reduced in comparison with the beginning of the treatment, but the clinical improvement was less than at the end of the treatment. We thus propose to realize real or sham rTMS sessions at 3 weeks interval during 6 months with subjects presenting a significant clinical improvement after a 3 week-rTMS or sham treatment to evaluate the response maintenance.
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Device: rTMS
    one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
  • Device: sham rTMS
    same session as defined with the real rTMS, but with a coil not delivering magnetic field.
  • Experimental: rTMS-rTMS
    subjects receiving real rTMS treatment and real rTMS maintenance sessions
    Intervention: Device: rTMS
  • Sham Comparator: sham - sham
    subjects receiving sham treatment and presenting a clinical improvement : they will be submitted to sham maintenance sessions
    Intervention: Device: sham rTMS
  • Sham Comparator: rTMS-sham
    subjects receiving sham rTMS maintenance sessions after successful real rTMS treatment
    • Device: rTMS
    • Device: sham rTMS
  • Experimental: rTMS
    real rTMS for 3 weeks but without clinical improvement
    Intervention: Device: rTMS
  • Sham Comparator: sham
    sham treatment for 3 weeks without clinical improvement
    Intervention: Device: sham rTMS
Ciobanu C, Girard M, Marin B, Labrunie A, Malauzat D. rTMS for pharmacoresistant major depression in the clinical setting of a psychiatric hospital: effectiveness and effects of age. J Affect Disord. 2013 Sep 5;150(2):677-81. doi: 10.1016/j.jad.2013.03.024. Epub 2013 May 11.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2017
August 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • presence of the criteria from the American College of Rheumatology (2010)for fibromyalgia diagnosis,
  • painful state for more than six months,
  • visual analogic scale evaluation > or = 5,
  • age between 18 and 70,
  • no modification in therapeutic treatment one month before and during the protocol
  • presence of actual or prior antalgic chronic treatment : pregabalin, duloxetine, milnacipran, gabapentin, venlafaxine, laroxyl, grade 1 or 2 antalgic
  • residence in Limoges or the periphery, or the ability to come to the hospital for the treatment

Exclusion Criteria:

  • presence of non stabilized psychiatric comorbidity (personality trouble, addiction, suicide attempt, non controlled affective trouble),
  • active epilepsy,
  • previous cerebral traumatism, or cerebral surgery, intra-cranial hyper tension,
  • pacemaker, metallic pieces in the brain, cochlear ocular implant, or any metallic material contra indicating magnetic resonance imaging.
  • clozapine, bupropion, methadon, theophyllin, or other non chemical antalgic technic established during the previous month(kinesitherapy, relaxation, hypnosis...),
  • pregnancy, or administrative and judiciary protection, absence of health insurance.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
Contact: Jean-Christophe Dumont, MD 0033555056870
Contact: Murielle Girard, PhD 0033555431028
Not Provided
Not Provided
Not Provided
Jean-Christophe Dumont, Centre Hospitalier Esquirol
Centre Hospitalier Esquirol
Not Provided
Principal Investigator: Jean-Christophe Dumont, MD CHU Dupuytren CH Esquirol
Centre Hospitalier Esquirol
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP